<DOC>
	<DOCNO>NCT01087762</DOCNO>
	<brief_summary>The study Phase 3 , multicenter , randomize , double-blind , placebo-controlled study evaluate efficacy safety two dose regimen Certolizumab Pegol ( CZP ) subject active axial Spondyloarthritis ( axial SpA ) .</brief_summary>
	<brief_title>Certolizumab Pegol Subjects With Active Axial Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Spondylarthropathies</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Documented diagnosis adultonset axial Spondyloarthritis ( SpA ) least 3 month ' duration define specified Assessment Spondyloarthritis International Society ( ASAS ) criteria Active disease define : Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) score ≥ 4 Back pain ≥ 4 0 10 Neurobehavioral Rating Scale ( NRS ) ( BASDAI item 2 ) CReactive Protein ( CRP ) &gt; ULN ( Upper Limit Normal ) and/or current evidence ( ie , within last 3 month Screening ) Sacroiliitis Magnetic Resonance Imaging ( MRI ) define Assessment Spondyloarthritis International Society ( ASAS ) criterion Intolerance inadequate response least 1 Nonsteroidal AntiInflammatory Drug ( NSAID ) Presence total Spinal Ankylosis ( `` bamboo spine '' ) Diagnosis Inflammatory Arthritis Prior treatment experimental biological agent treatment Axial Spondyloarthritis ( SpA ) Exposure 1 TNFantagonist 2 previous biological agent Axial Spondyloarthritis ( SpA ) History current chronic recurrent infection High risk infection Recent live vaccination Concurrent malignancy history malignancy Class III IV congestive heart failure New York Heart Association ( NYHA ) Demyelinating disease central nervous system Female subject breastfeeding , pregnant plan become pregnant study within 3 month follow last dose investigational product Subjects condition , investigator 's judgment , would make subject unsuitable inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
</DOC>